Obstet Gynecol. 2009 Apr;113(4):775-782.

Results From Four Rounds of Ovarian Cancer Screening in a Randomized Trial.
Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, Kessel B, Johnson CC, Weissfeld JL, Isaacs C, Andriole GL, Ogden S, Ragard LR, Buys SS; for the PLCO Project Team.

From the 1University of Alabama at Birmingham School of Medicine, Birmingham, Alabama; 2Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; 3Marshfield Medical Research and Education Foundation, Marshfield, Wisconsin; 4Information Management Services, Rockville, Maryland; 5University of Minnesota, Minneapolis, Minnesota; 6Pacific Health Research Institute, Honolulu, Hawaii; 7Henry Ford Health System, Detroit, Michigan; 8University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania; 9Lombardi Cancer Center, Georgetown University, Washington, DC; 10Washington University School of Medicine, St. Louis, Missouri; 11University of Colorado Cancer Center, University of Colorado Denver, Denver, Colorado; 12Westat, Inc., Rockville, Maryland; and 13Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah.

Objective:

: To test whether annual screening with transvaginal ultrasonography and CA 125 reduces ovarian cancer mortality. METHODS:: Data from the first four annual screens, denoted T0-T3, are reported. A CA 125 value at or above 35 units/mL or an abnormality on transvaginal ultrasonography was considered a positive screen. Diagnostic follow-up of positive screens was performed at the discretion of participants' physicians. Diagnostic procedures and cancers were tracked and verified through medical records. RESULTS:: Among 34,261 screening arm women without prior oophorectomy, compliance with screening ranged from 83.1% (T0) to 77.6% (T3). Screen positivity rates declined slightly with transvaginal ultrasonography, from 4.6 at T0 to 2.9-3.4 at T1-T3; CA 125 positivity rates (range 1.4-1.8%) showed no time trend. Eighty-nine invasive ovarian or peritoneal cancers were diagnosed; 60 were screen detected. The positive predictive value (PPV) and cancer yield per 10,000 women screened on the combination of tests were similar across screening rounds (range 1.0-1.3% for PPV and 4.7-6.2 for yield); however, the biopsy (surgery) rate among screen positives decreased from 34% at T0 to 15-20% at T1-T3. The overall ratio of surgeries to screen-detected cancers was 19.5:1. Seventy-two percent of screen-detected cases were late stage (III/IV). CONCLUSION:: Through four screening rounds, the ratio of surgeries to screen-detected cancers was high, and most cases were late stage. However, the effect of screening on mortality is as yet unknown.

Women's Health



women's health

Please click on the required question.



Your Own Web Presence

 

For £35

 

 

FirstWebSiteDesign.com

 

Have your own web ad on the internet and optimized for good positioning.

 

Your Own Dedicated Web Page Designed Specifically For You

 

More Effective

Than Your Own

Single Page Website

 

For £35

 

 

FirstWebSiteDesign.com